EFFECTIVENESS OF IMMUNOSUPPRESSIVE THERAPY IN KIDNEY TRANSPLANT SURGERY AND POSTOPERATIVE COMPLICATIONS: MODERN SURGICAL AND CLINICAL PERSPECTIVES

Abstract

End-stage renal disease remains one of the leading causes of morbidity and mortality worldwide and continues to represent a major challenge for modern nephrology and transplant surgery. Progressive deterioration of renal function results in severe metabolic abnormalities, cardiovascular disorders, immune dysfunction, and a substantial reduction in quality of life.

References

1. Halloran P.F. Immunosuppressive drugs for kidney transplantation // New England Journal of Medicine. – 2004. – Vol. 351. – P. 2715–2729.
2. Naesens M., Kuypers D.R.J., Sarwal M. Calcineurin inhibitor nephrotoxicity // Clinical Journal of the American Society of Nephrology. – 2009. – Vol. 4. – P. 481–508.
3. Fishman J.A. Infection in organ transplantation // American Journal of Transplantation. – 2017. – Vol. 17. – P. 856–879.
4. Webster A.C., Taylor R.S., Chapman J.R. Tacrolimus versus cyclosporine as primary immunosuppression for kidney transplant recipients // Cochrane Database of Systematic Reviews. – 2005. – CD003961.
5. Lamb K.E., Lodhi S., Meier-Kriesche H.U. Long-term renal allograft survival in the United States // American Journal of Transplantation. – 2011. – Vol. 11. – P. 450–462.
6. Hariharan S., Johnson C.P., Bresnahan B.A. Improved graft survival after renal transplantation in the United States // New England Journal of Medicine. – 2000. – Vol. 342. – P. 605–612.
7. Chapman J.R. Chronic calcineurin inhibitor nephrotoxicity // American Journal of Transplantation. – 2011. – Vol. 11. – P. 693–697.
8. Ekberg H., Tedesco-Silva H., Demirbas A. Reduced exposure to calcineurin inhibitors in renal transplantation // New England Journal of Medicine. – 2007. – Vol. 357. – P. 2562–2575.
9. Ojo A.O. Cardiovascular complications after renal transplantation and their prevention // Transplantation. – 2006. – Vol. 82. – P. 603–611.